Table 4.

Evaluation of the performance [C-statistic (95% CI)] of the GARFIELD-AF risk models vs. CHA₂DS₂-VASc (for all-cause mortality and non-haemorrhagic stroke/SE) or HAS-BLED (for major bleeding/haemorrhagic stroke) at 2 years of follow-up in the ORBIT-AF study population and Danish AF cohort

	ORBIT-AF		Danish AF cohort
	GARFIELD-AF	CHA2DS2-VASc/ HAS-BLED	GARFIELD-AF	CHA2DS2-VASc/ HAS-BLED
All-cause mortality	0.75 (0.74–0.76)	0.68 (0.67–0.69)	0.77 (0.77–0.78)	0.68 (0.67–0.68)
Non-haemorrhagic stroke/SE	0.68 (0.64–0.71)	0.67 (0.64–0.71)	0.69 (0.68–0.69)	0.66 (0.65–0.67)
Major bleeding/haemorrhagic stroke	0.64 (0.62–0.66)	0.63 (0.61–0.64)	0.67 (0.66–0.68)	0.63 (0.61–0.64)

ORBIT-AF: history of bleeding and carotid occlusive disease were not available; Danish AF cohort: blood pressure, BMI, pulse, smoking, and ethnicity were not available.

BMI, body mass index; CI, confidence interval; GARFIELD-AF, Global Anticoagulant Registry in the FIELD–Atrial Fibrillation; SE, systemic embolism.